Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
FibroGenesis has entered into a manufacturing agreement with iBiologics to supply its proprietary allogeneic fibroblast cells to support FibroGenesis's growing chronic disease platform and ongoing clinical trials.
read more
FIMECS has concluded a strategic licensing agreement with Takeda Pharmaceutical.
read more
RR&D has announced its official launch to address logistical challenges facing companies developing drugs, vaccines and medical devices.
read more
Thursday, September 30, 2021
Curavit Clinical Research, a virtual contract research organization (VCRO) that designs and executes decentralized clinical trials (DCTs), announced today that it has joined the Decentralized Trials & Research Alliance (DTRA) to further the ...
read more
Minaris Regenerative Medicine, a global manufacturing partner to the cell and gene therapy industry, today announced that the first commercial manufacturing run of LYFGENIA – a one-time gene therapy for the treatment of sickle cell disease developed ...
read more
Wednesday, November 02, 2022
First Wave BioPharma, Inc. announced that it has entered into an agreement with Rho, a full-service contract research organization (CRO), for its planned Phase 2 clinical trial of an enhanced enteric microgranule delivery formulation for adrulipase.
read more
Factory CRO has announced that Five Corners is joining the company.
read more
Five Prime Therapeutics announced UCB has elected to exclusively license an undisclosed drug target for inflammatory diseases. Five Prime identified the target using its discovery platform.
read more
Thursday, September 08, 2022
Flagship Biosciences announced the acquisition of Interpace Pharma Solutions ("IPS"), a division of Interpace Biosciences and provider of cytogenetic, molecular pathology, and genomic profiling solutions.
read more
Tuesday, February 07, 2023
Flagship Biosciences, a provider of spatial biology and biomarker analytics services, announced a strategic partnership with Genomenon® that aims to transform the drug development paradigm with accelerated biomarker discovery and companion ...
read more
Flamma announced the ground breaking for their new R&D building.
read more
Friday, November 13, 2020
Flamma entered into an agreement with Gilead earlier this year to be part of the network of manufacturers contributing to the Veklury supply chain.
read more
The Flamma Group, a company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry as well as a Contract Development and Manufacturing Organization (CDMO) of New Chemical Entities (NCEs) ...
read more
The Flamma Group has officially opened its current Good Manufacturing Practice (cGMP) plant in Dalian, China, expanding its global pharmaceutical manufacturing footprint. The grand opening ceremony marked the launch of the Flamma Honkai 2 facility, ...
read more
Friday, November 06, 2020
Flamma has entered into an agreement with Gilead earlier this year to be part of the network of manufacturers contributing to the Veklury (remdesivir) supply chain.
read more